Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David J. Bjorkman is active.

Publication


Featured researches published by David J. Bjorkman.


NEJM Journal Watch | 2002

Risk Factors for

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

As more patients in the U.S. undergo treatment for Helicobacter pylori infections, antibiotic resistance is emerging and is becoming an important


NEJM Journal Watch | 2009

and Gastric Cancer

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Helicobacter pylori infection increases the risk for gastric cancer, one of the most common cancers in the world. Studies designed to examine whether


NEJM Journal Watch | 2012

and Inflammatory Bowel Disease

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Some preliminary studies have suggested that patients with Helicobacter pylori infection are less likely to have inflammatory bowel disease (IBD) than


NEJM Journal Watch | 2007

Infection and Gastric Cancer

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Gastric cancer is a common cause of death worldwide, but with considerable geographic variation. Part of that variation might be due to differences in


NEJM Journal Watch | 2007

Adjuvant Chemotherapy for Gastric Cancer

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Gastric cancer is a major cause of mortality worldwide. Prognosis is poor unless the cancer is diagnosed at a very early stage. In Western countries,


NEJM Journal Watch | 2002

NSAIDs and H. pylori: A Dangerous Combination?

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) are independently associated with peptic ulcer disease, but the potential interaction between these factors is controversial. Large, population-based studies have failed to identify a synergistic effect, whereas results from cohort studies suggest both an additive risk and a protective effect associated with H. pylori infection and NSAID use. To examine whether H. pylori eradication reduces ulceration in patients taking NSAIDs, investigators in Hong Kong randomized 100 arthritis patients with H. pylori infection who were about to take NSAIDs for the first time to receive either 1 week of omeprazole-based antibiotic therapy for H. …


NEJM Journal Watch | 2012

Maneuverable Videocapsule Gastroscopy: Not Ready for Prime Time

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Capsule endoscopy has been used to evaluate the mucosa of the small and large bowel, but reliance on intrinsic bowel motility has impaired its use in


NEJM Journal Watch | 2009

EMR for Early Gastric Cancer

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Endoscopic mucosal resection (EMR) has become standard therapy in Asian countries that have a high incidence of early gastric cancer. Such cancer is


NEJM Journal Watch | 2007

Trends in Gastric Adenocarcinoma

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Previous reports suggest that the incidence of gastric cancer is declining in the U.S., perhaps because of a decrease in the prevalence of Helicobacter pylori infection. However, the incidence of noncardia gastric adenocarcinoma has not been well described. In this study, investigators searched the Surveillance, Epidemiology, and End Results (SEER) …


NEJM Journal Watch | 2005

NSAIDs, and Peptic Ulcer Bleeding

David J. Bjorkman; Msph (Hsa); Sm (Epid.)

Nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection are the most common causes of peptic ulcer bleeding. In an

Collaboration


Dive into the David J. Bjorkman's collaboration.

Researchain Logo
Decentralizing Knowledge